OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	571
Towards reparatory measures: blood donation, health systems, and men who have sex with men	452
In the trenches	219
Prioritising health equity alongside donation safety – Authors' reply	217
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	196
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	144
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	144
Correction to Lancet Haematol 2023; 10: e333–45	143
Correction to Lancet Haematol 2024; 11: e114–26	141
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria	136
Zanubrutinib-associated ecchymotic lesions	133
MRD-guided treatment cessation in multiple myeloma	121
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	108
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	104
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial	101
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	92
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	91
Blood cell defence against pathogens	90
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	89
Blood deserts: a vision to tackle blood inaccessibility	88
Bedside art is good medicine	84
International Society on Thrombosis and Haemostasis Congress 2023	84
Extensively distributed erythema nodosum in VEXAS syndrome	84
Be compliant or compromise?	81
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	80

Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	78
Production and supply of blood products in Brazil	78
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	78
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	76
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	76
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	73
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	73
USAID's enduring impact on anaemia management must be preserved	69
Anaemia in a time of climate crisis	68
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	65
Coexisting genetic abnormalities and thrombocytopenia	65
Sickle cell disease in India: current status and progress	64
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	62
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	61
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	61
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	60
Correction to Lancet Haematol 2025; 12: e294–303	57
Correction to Lancet Haematol 2023; 10: e433–44	57
Rituximab versus active surveillance in patients with follicular lymphoma	55
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	54
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	54
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	53
Oreofe Odejide—aiming to raise the bar in haematology care	53
Correction to Lancet Haematol 2022; 9: e200–07	51
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	48
Correction to Lancet Haematol 2024; 11: e310–11	48
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	48
Could improving mental health disorders help increase cancer survival?	47
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	46
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	46
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	45
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	45
Universal health coverage for children with cancer	44
Striking the right balance	44
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	44
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	44
An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass	44
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	42
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	42
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	40
Secondary haematological malignancies	40
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	38
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	37
Should patients with haemophilia receive gene therapy?	37
Acute myeloid leukaemia at the extremes	36
Updated anaemia estimates: implications for global monitoring	36
Patients first: improving toxicity assessment and reporting	36
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors' reply	36
2024 ASH Annual Meeting	36
Correction to Lancet Haematol 2024; 11: e521–29	35

A long-awaited benchmark in lymphomatoid granulomatosis	35
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label,	35
Haemophilia—unparalleled progress but inadequate access	35
Haematology and climate change	35
Sickle cell disease—unity and patient-centred education	34
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial	33
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	33
The challenge of defining the global burden of iron deficiency anaemia	33
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	33
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	32
The Lancet Haematology at 10	31
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	31
Leprosy and leukaemia: an unexpected interaction	31
Thank you to The Lancet Haematology's peer reviewers in 2022	30
Sovleplenib in immune thrombocytopenia	29
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	29
Life beyond blood disorders	29
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	28
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial	28
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	28
Gene therapy in China: past, present, and future	28
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	28
Breaking sex biases: access for all in haemophilia care	28
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	28
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	28
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	28
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	28
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	27
Needles were the least of my worries	27
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	27
Don Thomas: leading the charge to bone marrow transplantation	26
Acquired haemophilia in an Edo period Japanese surgical casebook	26
Monumen-TAL progress in the treatment of relapsed multiple myeloma	25
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	25
A treatise on clinical trials	25
Experience of the Anaemia Mukt Bharat anaemia control programme in India	25
Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial	25
From diagnosis to equitable care in bleeding disorders	24
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	24
Clinical trial design change implementation for inclusive studies	23
Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England	23
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	23
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	22
Making a case for disease-modifying agents in myelofibrosis	21
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	21
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	21
Virtual twins for personalised CAR T-cell therapy in myeloma	21
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	21
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	21
Antifibrinolytics do not add to the benefits of platelet transfusion	20
Making blood count	20
Lines of the haematology community	20
Mitapivat for treatment of pyruvate kinase deficiency	20
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	20
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM	20
Reducing toxic waste: improving toxicity capture in childhood cancer	20
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	19
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	19
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	19
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	19
2025 ASH Annual Meeting	19
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	18
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, sing	18
Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue	18
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	18
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	17
Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990–2023: a population-based modelling study	17
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	17
Epistemic limitations of measurable residual disease in haematological malignancies	17
The effects of revised haemoglobin cutoffs on the global burden of anaemia	17
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	17
Correction to Lancet Haematol 2025; 12: e562–63	17
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	17
Sickle cell disease: a neglected health priority	17
Correction to Lancet Haematol 2023; 10: e203–12	16
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	16
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial	16
Reactivating hope for TP53-mutated acute myeloid leukaemia?	15
New hope, old challenges in myelodysplastic syndromes	15
Correction to Lancet Haematol 2024; 11: e862–72	15

Lallindra Gooneratne—maintaining treatment flow amid crisis	15
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	15
Time to define and refine maintenance strategies in acute myeloid leukaemia	15
Iron deficiency anaemia—an ongoing challenge	15
Sexually transmitted infections in the context of haematological malignancies	15
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	14
From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials	14
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	14
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	14
Long term strategies for individuals with sickle cell disease	14
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	14
Concerns on perioperative anaemia management in the FIT trial	13
Isolated IgG4-related disease of the left maxillary antrum	13
An integrated approach to cardioprotection in lymphomas	13
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	13
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	13
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	13
Oncology service priorities for the new UK Government	13
Virginia Abello Polo—a once-in-a-lifetime opportunity	12
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	12
Correction to Lancet Haematol 2025; 12: e128–37	12
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	12
Fitusiran prophylaxis in severe haemophilia without inhibitors	12
Correction to Lancet Haematol 2025; 12: e808–22	12
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	12
Correction to Lancet Haematol 2023; 10: e713–34	12
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	12
CAR T-cell therapies in China: rapid evolution and a bright future	11
Mental health and psychological resilience in sickle cell disease	11
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	11
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	11
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	11
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	11
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial	11
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial	11
CAR T-cell therapy: navigating real-world challenges beyond clinical trials	10
Overcoming the unmet need of Richter transformation: the use of pirtobrutinib	10
Cristóbal Frutos: confronting treatment barriers	10
Environmental impact of haematology care—measurement and mitigation	10
Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India	10
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials	10
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	10
Correction to Lancet Haematol 2025; 12: e978–85	9
Correction to Lancet Haematol 2024; 11: e510–20	9
Correction to Lancet Haematol 2024; 11: e38–50	9
Ending the burden of sickle cell disease in Africa	9
Prioritising health equity alongside donation safety	9
Lessons from both sides of the bedrail	9
Global equity in paediatric cancer care	8
A curious case of a neutrophilic horn	8
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	8
Can ropeginterferon SURPASS resistance in essential thrombocythaemia?	8
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia	8
Adverse event grading: the case of Duffy null-associated neutrophil counts	8
The dystopia of enforced childbirth	8
Maintaining MOMENTUM in myelofibrosis	8
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach	7
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase	7
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial	7
Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10	7
Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study	7
Radiotherapy for haematological malignancies	7
51st Annual Meeting of the EBMT	7
Ferritin-guided iron supplementation as an alternative or complement to prolonged blood donation intervals (FORTE): a double-blind, randomised, controlled trial	7
Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care	7
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021	7
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial	7
IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study	7
Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma	7
Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled tri	7
Establishing a sustainable academic point-of-care network for CAR T-cell therapy	7
Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures	6
Blastic plasmacytoid dendritic cell neoplasm with aberrant cytoplasmic CD3 expression	6
Assessing authorship of clinical practice guidelines	6
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analys	6
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma	6
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?	6
Advancements in haemophilia A and health equity: is it time to redefine severity?	6
Factors to consider when assessing the IDOCS study	6
Optimising treatment of HIV-associated Hodgkin lymphoma	6
Correction to Lancet Haematol 2024; 11: e459–70	6
Luspatercept in patients with non-transfusion dependent β-thalassaemia	6
Haematological malignancies in pregnancy: time for accurate incidence data	6
Expanding treatment options for warm autoimmune haemolytic anaemia	5
Sickle cell heroes	5
Ferritin-guided iron supplementation in blood donors – Authors' reply	5
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase	5
Diagnosis and management of Evans syndrome in adults: first consensus recommendations	5
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study	5
Venetoclax and acute myeloid leukaemia: an expanding new frontier	5
Darbepoetin alfa to reduce transfusion episodes in infants with haemolytic disease of the fetus and newborn who are treated with intrauterine transfusions in the Netherlands: an open-label, single-cen	5
Time trends in antithrombotic therapy during pregnancy and maternal and perinatal outcomes in the Netherlands (2013–19): a nationwide cohort study	5
Thalassaemia: advocacy, resilience, and adaptability	5
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study	5
Cecilia Guillermo—leading Uruguay's battle against haematological diseases	5